Community-acquired pneumonia (CAP) is the leading infectious cause of death in developed countries. Several studies have shown that the risk of pneumonia is increased in patients with chronic obstructive pulmonary disease (COPD) who are receiving chronic inhaled corticosteroids (ICS). The impact of ICS on pneumonia prognosis is controversial. Recent studies have shown that COPD patients with prior ICS use have less mortality after developing CAP as compared with patients with COPD without prior ICS use. This review discusses the association of ICS and the risk of CAP and its association with clinical outcomes in patients with COPD and pneumonia.
C ommunity-acquired pneumonia (CAP) is the leading infectious cause of death in developed countries. It affects more than 5 million adults and accounts for more than 1 million admissions each year in the United States. 1, 2 Pneumonia and influenza are the eighth leading causes of death in the United States, and age-adjusted mortality attributable to these illnesses is increasing. 3 It has been shown that the risk of developing pneumonia is increased in patients with chronic obstructive pulmonary disease (COPD), but is even higher for those who are receiving chronic inhaled corticosteroids (ICS). [4] [5] [6] The impact of ICS on pneumonia mortality is controversial, and recent studies have shown that COPD patients with prior ICS use have better clinical outcomes after developing CAP as compared with COPD patients without prior ICS use. 7, 8 The main purpose of this report is to review the evidence behind the association of ICS and the risk of CAP, and whether ICS use is associated with worse clinical outcomes in CAP patients. For this purpose we performed a review of published articles in the English language with the following search terms: inhaled corticosteroids and pneumonia.
ICS
ICS are anti-inflammatory agents widely used in patients with obstructive airways diseases. On the basis of their established efficacy and adequate safety profile these medications are recommended in the treatment of the most prevalent chronic respiratory diseases such as asthma and COPD. 9, 10 ICS agents currently available are: beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate, mometasone furoate (mometasone), triamcinolone acetonide (triamcinolone), and ciclesonide. Table 1 shows all current ICS and their therapeutic doses.
MECHANISM OF ACTION
ICS are known to exert their effects by binding to a glucocorticoid receptor located in the cytoplasm of target cells. Once activated, the drug-receptor complex moves into the nucleus of the cell and binds to the DNA and directly or indirectly regulates the transcription of target genes. Through the mechanisms of transactivation, corticosteroids may inhibit the transcription of proinflammatory cytokines and chemokines and upregulate production of anti-inflammatory proteins. The drug-receptor complex may also interact with DNAbinding transcription factors to repress proinflammatory protein production. 11 The potency of a given corticosteroid is governed by the affinity of the drug to bind to the glucocorticoid receptor. Receptor affinity is usually measured relative to dexamethasone. Of the currently available compounds, mometasone has the highest relative receptor affinity, followed by fluticasone and the active metabolites of beclomethasone (17-BDP monopropionate) and ciclesonide (des-CIC). [12] [13] [14] 
INDICATIONS
The main indications for the use of ICS are in COPD and asthma. 9 In COPD patients, ICS are only approved to be used in combination with long-active b-agonists (LABA). Nonwell-established indications are in other lung pathologies with bronchial hyperreactivity.
In COPD, ICS effects on airway inflammation are still controversial, but they have been demonstrated to reduce the overall frequency of exacerbations and improve quality of life. 15, 16 Thus, ICS are important anti-inflammatory therapy in COPD and are approved in different doses. For example, in the United States the dose of fluticasone is 250 mg twice a day, whereas in Europe it is >500 mg twice a day. They are recommended in symptomatic patients with a forced expiratory volume in the first second of expiration of <50% predicted (stage III, severe COPD; stage IV, very severe COPD) and frequent exacerbations. 10 In asthma, ICS are effective at suppressing airway inflammation and are the preferred controller medication. In addition, ICS improve asthma control more effectively than any other single long-term controller medication. ICS are the only asthma medication that have been shown to reduce mortality and the risk of hospitalization. 17 Therapeutic benefit is obtained at low doses such as fluticasone 200 mg/d or the equivalent 18 whereas adverse effects increase with higher doses. 19 These medications are recommended in persistent asthma and are indicated in all symptomatic patients. 9, 20 
SIDE EFFECTS
Potential ICS-related side effects are shown in Table 2 . ICS are delivered using metered-dose inhaler or dry powder inhaler device. Initially, a large proportion of the ICS is swallowed. Oral bioavailability depends on absorption characteristics from the gastrointestinal tract, lipophilicity of the compound, and the extent of first-pass metabolism. These absorptions range from 1% (fluticasone) to 26% (active metabolite of beclomethasone) for currently available compounds. Local adverse events described include oropharyngeal candidiasis, hoarseness and dysphonia, pharyngeal irritation, and cough. 21 Pulmonary bioavailability depends on the amount of ICS deposited in the lungs. It differs for different delivery devices and ranges from 11% for mometasone delivered by a dry powder inhaler to 52% for the active metabolite of ciclesonide. Once it reaches the circulation, most of the absorbed drug binds to plasma proteins. 22, 23 Only the unbound fraction is pharmacologically active. All current ICS are cleared by the liver. Despite the general acceptance of ICS over the past several decades, substantial concerns about their undesirable effects have occurred. The systemic effects of ICS are caused by their absorption into the systemic circulation. ICS, usually high doses, have been shown to increase the risk of skin bruising, hyperglycemia in diabetics, and the risk of adrenocorticol suppression (at unlabeled unapproved high doses). 21, 22 The risk of glaucoma, cataract formation, and osteoporotic fractures have, as of yet, been inconclusive in COPD patients on ICS agents. [24] [25] [26] Finally, recent studies have suggested an increased risk of pneumonia associated with moderate to high doses of ICS in COPD patients. [4] [5] [6] ICS AND PNEUMONIA Different studies have evaluated the relationship between ICS use and risk of pneumonia (Table 3) . Several recent studies have demonstrated that the use of ICS was associated with an increased risk of CAP in COPD patients. [4] [5] [6] However, this increased risk has been not described in other diseases such asthma. 35 COPD is a common disease and the fourth leading cause of morbidity and mortality in the United States. 36, 37 The disease represents a substantial public health burden, affecting 10 to 15 million persons in the United States. 38 ICS therapy is central to the long-term management of COPD. Elevated levels of systemic and pulmonary inflammation in stable COPD patients have led to the use of ICS therapy for these patients. The results of the majority of ICS trials in COPD have conflicting results regarding their effects on airway inflammation, but the use of ICS has been shown to reduce the incidence of exacerbations and improve health status in these patients. Therefore, current international guidelines recommend ICS therapy in addition to bronchodilators for severe COPD patients and those with frequent exacerbations. 10 The mechanism of the association of ICS therapy with pneumonia remains unclear. ICS achieve local high concentrations in the lungs and may increase the risk of pneumonia because of their immunosuppressive effects. 39, 40 Barnes et al 41 demonstrated that the combination of fluticasone and salmeterol significantly reduces the inflammatory cells in bronchial biopsies and decrease the expression of proinflammatory mediators. This hypothesis is supported by a multicenter trial that suggested that ICS use reduces local but not systemic biomarkers of inflammation in patients with COPD. 42 Inhaled fluticasone at doses of 1000 mg/d exerts effects on serum cortisol levels that are equivalent to 10 mg of oral prednisone. Patients with advanced COPD who are at the highest risk of colonization with potentially pathogenic bacteria may be uniquely susceptible to these local immunosuppressive effects. In addition, Gutierrez et al 43 demonstrated that the microenvironment of the lungs modulates the macrophage activation in exacerbated COPD with and without CAP. In asthma, in contrast, the use of ICS does not seem to increase the risk of pneumonia. O'Byrne and colleagues, in a recent meta-analysis of randomized clinical trials of budesonide compared with placebo or fluticasone in patients with asthma did not demonstrate an increased risk of pneumonia when ICS was compared with non-ICS treatment. In addition, there was no evidence of increased risk of pneumonia with higher doses of budesonide, or any difference when budesonide was compared with fluticasone. 35 
ICS AND RISK OF PNEUMONIA IN COPD PATIENTS
The TORCH (Towards a Revolution in Chronic Obstructive Pulmonary Disease Health) study, 4 was the first large randomized controlled trial (RCT) suggesting an excess in pneumonia events in COPD patients who received ICS. This study compared the efficacy of fluticasone propionate, salmeterol or their combination (salmeterol/fluticasone 50/500 mg twice daily) versus placebo in COPD patients over a 3-year period. Patients receiving ICS (fluticasone propionate, whether as monotherapy or in combination with LABA) had higher rate of physician reported pneumonia (19.6% and 18.3%, respectively) when compared with the placebo group, 12.3% (P < 0.001). 4 The main limitation of this finding was the lack of radiologic pneumonia confirmation. Further review of these data, did not establish a relationship between pneumonia and increased risk for COPD exacerbations, hospitalizations, or mortality. 44 The association between ICS and pneumonia in COPD patients has been reported in 2 other large RCTs (Table 4) . Kardos et al, 5 assessed the impact of combination therapy of salmeterol/fluticasone propionate 50/500 mg twice daily compared with LABA alone on moderate and severe AECOPD in patients with severe COPD. The study authors concluded that LABA + ICS therapy reduced the rate of moderate and severe AECOPD in these patients by 35% (P < 0.001). However, more pneumonia events were reported in the ICS + LABA group compared with the LABA alone group (4.5% vs. 1.4%, P = 0.005). In addition, Wedzicha et al, 6 evaluated the effect on reducing COPD exacerbations of the combination of salmeterol/fluticasone propionate 50/500 mg twice daily against tiotropium in COPD patients. They also found an increased rate of pneumonia events in the fluticasone-containing regimen (8% vs. 4%, P = 0.008). In a subsequent review of these data, the investigators concluded that pneumonia is less frequent than exacerbations, and seemed to be present in patients that had persistent exacerbation symptoms, suggesting that early identification and treatment of exacerbations may decrease the risk for pneumonia. 45 Ernst et al, 28 in a large observational study in Canada of over 175,000 patients, found that elderly patients with COPD with a current prescription for an ICS were 70% more likely to be hospitalized with a primary diagnosis of pneumonia [relative risk (RR) 1.70; 95% confidence interval (CI), 1.63-1.77; P < 0.001]. The number of elderly COPD patients that were hospitalized with pneumonia was 23,942, which corresponds to a rate of 1.9 per 100 per year. In addition, these data suggested that there was a 2-fold increased risk of hospitalization in the entire sample and the risk was greatest with higher doses of ICS (fluticasone propionate of 1000 mg/d). Mullerova et al 29 showed an increased risk of CAP among COPD patients in a recent observational study examining a cohort of 40,411 COPD patients. In this study, the increased risk of CAP in COPD patients was independently associated with prior exacerbations requiring hospitalization [odds ratio (OR) 2.7; 95% CI, 2.3-3.2], severe COPD requiring home oxygen or nebulized therapy (OR 1.4; 95% CI, 1.1-1.6), and specific comorbidities such as dementia (OR 2.6; 95% CI, 1.9, 3.0) and congestive heart failure (OR 1.4; 95% CI, 1.2-1.6).
In contrast, an RCT by Welte et al 27 assessed the efficacy of budesonide/formoterol added to tiotropium in patients eligible for ICS/LABA combination therapy. The authors concluded that budesonide/formoterol added to tiotropium versus tiotropium alone provided rapid and sustained improvements in lung function, health status, morning symptoms and activities, and reduced AECOPD. There were only 3 cases of pneumonia within each treatment group (< 1%), which is consistent with previous smaller RCT studies. 46, 47 Finally, several meta-analyses have also evaluated the relationship between ICS and pneumonia in COPD patients. Drummond et al 30 evaluated 11 RCT of ICS therapies in patients with stable COPD, and concluded that ICS therapy was associated with a 34% increased risk of pneumonia. Singh et al 31 assessed the results of 18 trials that included 16,996 patients, and showed that the use of ICS was associated with a significantly increased risk of any pneumonia event when compared with controls (RR 1.60; 95% CI, 1.33-1.92; P < 0.001). Rodrigo et al 32 evaluated the association of ICS and important adverse events including pneumonia and reached the same conclusions. In addition, Singh and Loke, 33 in a more recent trial-level meta-analysis, which was a revised and 27 102 centers in 9 countries T + BF (n = 331); T + placebo (n = 329) Incidence <1% in each group (P = NS) BF indicates budesonide/formoterol; CI, confidence interval; F, fluticasone; NS, not significant; S, salmeterol; SFC, salmeterol/fluticasone; T, tiotropium.
updated version of a previous meta-analysis, 31 showed that inhaled fluticasone and mometasone exposure remain significantly associated with an increase in the risk of pneumonia. In addition, they reported a numerical increase in the risk of pneumonia with budesonide exposure, but not statistically significantly different (RR 1.1; 95% CI, 0.9-1.5). In contrast, a meta-analysis of individual patient data restricted to clinical trials of budesonide treatment for 12 months in patients with COPD, did not find an excess of pneumonia events. 34 In all of these studies, the main limitation was the use of a nonconsistently objective definition of pneumonia without radiologic confirmation in most of the cases. Therefore, the data suggest that there is an increased risk of developing pneumonia events while exposed to ICS. However, because of the lack of radiologic confirmation, the assessment of severity of illness of pneumonia at diagnosis, the rate of influenza and/or pneumonia vaccination, and other potential unmeasured confounders, it remains a matter of controversy.
PNEUMONIA-RELATED MORTALITY IN COPD PATIENTS TAKING ICS
The evidence from RCTs and meta-analyses suggest that the increased risk of pneumonia associated with ICS may not translate to poor outcomes in those subjects who developed pneumonia. In the TORCH study, 4 there were no statistically significant differences among groups in the overall mortality rate. Similarly, in the INSPIRE study, 6 the authors demonstrated a lower death rate in the ICS + LABA group (salmeterol/ fluticasone propionate 50/500 mg twice daily in combination) compared with tiotropium. The meta-analyses by Drummond et al 30 and Singh et al 31 found no differences in overall mortality among ICS and non-ICS users. More specifically, Singh and Loke 33 reported a trial level meta-analysis on pneumonia (adverse events and serious adverse events) and pneumoniarelated mortality, and showed that the increased risk of pneumonia was not accompanied by an increased risk of pneumonia-related mortality.
Two observational studies using large administrative databases in COPD patients hospitalized with pneumonia, showed a decreased risk of mortality among the ICS users group. Malo de Molina et al, 7 in a cohort of 6353 patients admitted with pneumonia and prior COPD, demonstrated that outpatient therapy with ICS was associated with a significantly lower 30-day and 90-day mortality. Subsequently, Chen et al, 8 in a different cohort of 15,768 COPD patients hospitalized with pneumonia who received ICS, found an independent association with a decreased risk of short-term mortality and use of mechanical ventilation after hospitalization for pneumonia. In contrast, Ernst et al 28 reported in a cohort of 23,942 patients with COPD and pneumonia an increase in 30-day mortality associated with pneumonia, secondary to ICS use [adjusted rate ratio (RR) 1.53, 95% CI, 1.30-1.80]. The increased risk of CAP was associated with higher doses of ICS. In this study, all-cause mortality was similar for patients hospitalized for pneumonia, whether or not they had received ICS in the recent past. Finally, a prospective study conducted in 490 spirometry-confirmed COPD patients with a primary diagnosis of CAP did not find differences in 30-day mortality among ICS and non-ICS users. 48 
CONCLUSIONS
The use of ICS in COPD patients is common practice with benefits of reducing the rate of COPD exacerbations, and improving symptoms and quality of life. However, it is concerning that the data are highly suggestive of an increased risk of the development of pneumonia, although the risk of acquiring pneumonia may not translate to higher mortality among ICS users who require hospitalization for pneumonia.
Further studies with rigorously defined pneumonia and exacerbation outcomes, of sufficient duration and sample size are required to further clarify these issues. Clinicians should remain particularly vigilant for the development of pneumonia in COPD patients on ICS. Instructions and recommendations should be given to patients, as the signs and symptoms of pneumonia may mimic COPD exacerbations.
